Diabetes Unit, "S. Camillo-Forlanini" Hospital, Rome, Italy.
Acta Diabetol. 2022 Oct;59(10):1287-1294. doi: 10.1007/s00592-022-01936-6. Epub 2022 Jul 17.
Aim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM.
This was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ).
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating.
The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.
本研究旨在评估每周一次司美格鲁肽对 2 型糖尿病（T2DM）代谢控制、心血管风险、饮食行为和治疗满意度等不同终点的影响。
这是一项在糖尿病诊所进行的回顾性观察性研究。分析了首次处方司美格鲁肽（T0）后 32 周（T1）时 HbA1c、空腹血糖（FBG）、体重、血压、血脂谱和降压药数量的变化。此外，在 T1 时，患者被要求填写糖尿病治疗满意度问卷（DTSQ）和饮食控制问卷（COEQ）。
总共确定了 104 名患者（平均年龄 63.6±10.4 岁，58.7%为男性，糖尿病病程 12.7±8.7 年）。用司美格鲁肽治疗 32 周后，HbA1c 水平降低了 1.38%，FBG 降低了-56.53mg/dl，体重降低了 6.03kg。收缩压和舒张压、总胆固醇、HDL-胆固醇、LDL-胆固醇、非-HDL 胆固醇和甘油三酯均显著改善。降血糖药和降压药的数量也减少了。在 T1 时，DTSQ 评分为 32.23±1.44，而 COEQ 表明饥饿感低，饮食控制良好。
该研究记录了司美格鲁肽在代谢控制和多种心血管危险因素方面的益处，治疗方案简化，糖尿病治疗满意度高，以及饮食行为表明健康饮食和减少食物摄入。
